These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17517836)

  • 1. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
    Hecht DW; Galang MA; Sambol SP; Osmolski JR; Johnson S; Gerding DN
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2716-9. PubMed ID: 17517836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.
    Barbut F; Decré D; Burghoffer B; Lesage D; Delisle F; Lalande V; Delmée M; Avesani V; Sano N; Coudert C; Petit JC
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2607-11. PubMed ID: 10543736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.
    Karlowsky JA; Laing NM; Zhanel GG
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4163-5. PubMed ID: 18725442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile.
    Huhulescu S; Sagel U; Fiedler A; Pecavar V; Blaschitz M; Wewalka G; Allerberger F; Indra A
    J Med Microbiol; 2011 Aug; 60(Pt 8):1206-1212. PubMed ID: 21292853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.
    O'Connor JR; Galang MA; Sambol SP; Hecht DW; Vedantam G; Gerding DN; Johnson S
    Antimicrob Agents Chemother; 2008 Aug; 52(8):2813-7. PubMed ID: 18559647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.
    Liao CH; Ko WC; Lu JJ; Hsueh PR
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3943-9. PubMed ID: 22508299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In Vitro Activities of Antimicrobials Against Toxigenic Clostridioides difficile Isolates Obtained in a University Training and Research Hospital in Turkey].
    Sayın E; Bilgin H; Söyletir G; Ülger Toprak N
    Mikrobiyol Bul; 2020 Jul; 54(3):368-377. PubMed ID: 32755514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of linezolid against Clostridium difficile.
    Peláez T; Alonso R; Pérez C; Alcalá L; Cuevas O; Bouza E
    Antimicrob Agents Chemother; 2002 May; 46(5):1617-8. PubMed ID: 11959617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity to antibiotics of Clostridium difficile toxigenic nosocomial strains.
    Beran V; Chmelar D; Vobejdova J; Konigova A; Nemec J; Tvrdik J
    Folia Microbiol (Praha); 2014 May; 59(3):209-15. PubMed ID: 24114414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
    Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
    Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.
    Goldstein EJ; Citron DM; Sears P; Babakhani F; Sambol SP; Gerding DN
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5194-9. PubMed ID: 21844318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas.
    Jiang ZD; DuPont HL; La Rocco M; Garey KW
    J Clin Pathol; 2010 Apr; 63(4):355-8. PubMed ID: 20354207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
    Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
    J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.
    Mathur H; O'Connor PM; Hill C; Cotter PD; Ross RP
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2882-6. PubMed ID: 23571539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole.
    Peláez T; Alcalá L; Alonso R; Martín-López A; García-Arias V; Marín M; Bouza E
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1157-9. PubMed ID: 15728918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
    Peláez T; Alcalá L; Alonso R; Rodríguez-Créixems M; García-Lechuz JM; Bouza E
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1647-50. PubMed ID: 12019070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibility of Brazilian Clostridium difficile strains determined by agar dilution and disk diffusion.
    Fraga EG; Nicodemo AC; Sampaio JL
    Braz J Infect Dis; 2016; 20(5):476-81. PubMed ID: 27542867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronidazole resistance in Clostridium difficile is heterogeneous.
    Peláez T; Cercenado E; Alcalá L; Marín M; Martín-López A; Martínez-Alarcón J; Catalán P; Sánchez-Somolinos M; Bouza E
    J Clin Microbiol; 2008 Sep; 46(9):3028-32. PubMed ID: 18650353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period.
    Drummond LJ; McCoubrey J; Smith DGE; Starr JM; Poxton IR
    J Med Microbiol; 2003 Mar; 52(Pt 3):259-263. PubMed ID: 12621092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.